ADMA Biologics (NASDAQ:ADMA) Shares Gap Up – Here’s What Happened

ADMA Biologics Inc (NASDAQ:ADMA)’s share price gapped up before the market opened on Friday . The stock had previously closed at $8.29, but opened at $9.47. ADMA Biologics shares last traded at $9.2850, with a volume of 7,779,818 shares.

ADMA Biologics News Summary

Here are the key news stories impacting ADMA Biologics this week:

• Positive Sentiment: Company issues formal refutation of Culper Research’s allegations, calling the report “unsubstantiated, misleading and inaccurate” and defending ASCENIV’s competitive position and revenue recognition. ADMA refutes short-seller claims
• Positive Sentiment: Market coverage notes a rebound after the company’s rebuttal — headlines and articles report ADMA “gains” as traders react to management’s statements. ADMA gains after refuting claims
• Positive Sentiment: Analysts and media flag market attention including Nasdaq reactions and commentary that the company is actively addressing investor concerns — helpful for short‑term sentiment. Market attention coverage
• Neutral Sentiment: Unusual options activity was reported (large call buying), suggesting speculative positioning that can amplify intraday moves but not fundamental direction. (Options volume reported in market notices.)
• Neutral Sentiment: Context pieces note ADMA is down significantly since its last earnings release, highlighting volatility tied to recent results and expectations — useful for evaluating risk vs. reward. Zacks: stock down since earnings
• Negative Sentiment: Multiple securities‑fraud investigations and investor alerts have been launched by a number of law firms after the short report and the subsequent price decline — this increases legal risk and could pressure the stock. Investor investigations announced
• Negative Sentiment: Short‑seller allegations (including claims of channel stuffing) remain in circulation via reports and investor alerts; third‑party scrutiny prompted steep intraday declines last week and remains a key downside risk. Investor alert on short‑seller report
• Negative Sentiment: Cantor Fitzgerald moved the stock after the short‑report fallout (coverage/ratings action reported), adding analyst pressure on sentiment. Cantor Fitzgerald downgrade

Wall Street Analyst Weigh In

Several brokerages recently weighed in on ADMA. Weiss Ratings reiterated a “hold (c)” rating on shares of ADMA Biologics in a research report on Tuesday, December 23rd. Zacks Research upgraded shares of ADMA Biologics from a “hold” rating to a “strong-buy” rating in a research report on Monday, March 2nd. Wall Street Zen upgraded shares of ADMA Biologics from a “hold” rating to a “buy” rating in a research note on Saturday, February 28th. Finally, Cantor Fitzgerald reiterated a “neutral” rating on shares of ADMA Biologics in a research report on Thursday. Two research analysts have rated the stock with a Strong Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat.com, ADMA Biologics has a consensus rating of “Buy” and a consensus price target of $32.00.

ADMA Biologics Stock Up 11.6%

The company has a debt-to-equity ratio of 0.16, a current ratio of 6.71 and a quick ratio of 3.74. The stock has a market capitalization of $2.20 billion, a P/E ratio of 15.42 and a beta of 0.51. The stock’s fifty day moving average is $15.60 and its two-hundred day moving average is $16.42.

ADMA Biologics (NASDAQ:ADMA) last posted its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $0.20 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.20. ADMA Biologics had a return on equity of 37.52% and a net margin of 28.80%.The company had revenue of $139.16 million for the quarter, compared to analysts’ expectations of $139.80 million. During the same quarter in the prior year, the company earned $0.46 earnings per share. The firm’s revenue was up 18.4% on a year-over-year basis. As a group, research analysts predict that ADMA Biologics Inc will post 0.51 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Director Steve Elms bought 7,000 shares of ADMA Biologics stock in a transaction dated Thursday, March 5th. The stock was acquired at an average cost of $15.67 per share, with a total value of $109,690.00. Following the completion of the acquisition, the director directly owned 2,038,730 shares in the company, valued at approximately $31,946,899.10. This trade represents a 0.34% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, COO Kaitlin M. Kestenberg-Messina sold 10,096 shares of the stock in a transaction on Monday, March 9th. The shares were sold at an average price of $15.63, for a total value of $157,800.48. Following the completion of the transaction, the chief operating officer owned 466,600 shares of the company’s stock, valued at $7,292,958. This trade represents a 2.12% decrease in their position. The disclosure for this sale is available in the SEC filing. 3.50% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in ADMA. Salomon & Ludwin LLC purchased a new position in shares of ADMA Biologics in the third quarter worth approximately $25,000. Rothschild Investment LLC lifted its position in shares of ADMA Biologics by 373.8% in the 3rd quarter. Rothschild Investment LLC now owns 1,895 shares of the biotechnology company’s stock valued at $28,000 after acquiring an additional 1,495 shares in the last quarter. Summit Securities Group LLC purchased a new stake in shares of ADMA Biologics in the 4th quarter valued at approximately $29,000. Clearstead Advisors LLC boosted its stake in ADMA Biologics by 55.7% in the 3rd quarter. Clearstead Advisors LLC now owns 2,222 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 795 shares during the period. Finally, iSAM Funds UK Ltd acquired a new position in ADMA Biologics in the 3rd quarter worth approximately $34,000. 75.68% of the stock is currently owned by institutional investors and hedge funds.

ADMA Biologics Company Profile

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.